Leukocytoclastic vasculitis after coronavirus disease 2019 vaccination

Abstract

The ChAdOx1 nCoV-19 vaccine (AstraZeneca®; UK) has been administrated against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Injection-site skin reaction has been reported as a common adverse drug reaction; however, there has been only one report of vasculitis so far with the ChAdOx1 nCoV-19 vaccine.1 Herein, we present a case of new-onset leukocytoclastic vasculitis following ChAdOx1 nCoV-19 vaccination. A 68-year-old Korean woman presented with asymptomatic erythematous to purpuric non-blanching macules on both lower extremities for 2 days (Figure 1a,b). Concomitant symptoms including fever, arthralgia, abdominal pain, or hematuria were denied. She had received the first vaccination of ChAdOx1 nCoV-19 7 days prior to the onset of lesions. She denied any medical history, including vasculitis or medication. Laboratory finding revealed decreased C3 and C4 levels (68.3 and 2.4 mg/dL, respectively), but all other tests, including complete blood count, renal function test, urinalysis, and antinuclear antibody, were unremarkable. Histopathological examination showed perivascular and interstitial inflammatory infiltration with lymphocytes, neutrophils, eosinophils, and leukocytoclasia, with extravasation of a few erythrocytes (Figure 1c,d). She was treated with oral methylprednisolone (4 mg/day for 1 week, followed by 2 mg/day for 2 weeks), colchicine 1.2 mg/day, and topical methylprednisolone for 3 weeks. The lesions resolved and did not relapse after cessation of treatment. The lesion slightly recurred on the legs with the second vaccination, but resolved spontaneously in a few days. Polymorphic dermatological manifestations have been reported in coronavirus disease 2019 (COVID-19) patients. Giovanni et al.2 classified COVID-19-associated cutaneous manifestations into six clinical patterns, among which purpuric vasculitic patterns represented 7.1–15.4%. Histopathological findings of vasculitic lesions vary, including leukocytoclastic vasculitis, perivascular neutrophilic and lymphocytic infiltration, fibrin deposition, or endothelial swelling.2 Meanwhile, correlation with immunoglobulin A vasculitis has been described in case systemic manifestations were accompanied or skin lesions were distributed to extensive area of the body.3 The SARS-CoV-2 spike protein, which is a major component of the vaccine, has been suggested to activate alternative complement pathway through binding to mannose-binding lectin.4 Similar to complement-mediated endotheliopathy in COVID-19 patients, the SARS-CoV-2 spike protein may have induced complement activation or autoimmunity, thereby leading to the inflammation of the cutaneous microvasculature. Unlike the case of cutaneous vasculitis after other COVID-19 vaccinations such as BNT162b2 (Pfizer®; USA),5 the decreased C3 and C4 levels in our patient reveal a clearer association between vascular injury and complement activation. The different characteristics of vaccines, including gene delivery mechanism or adjuvants, might cause variable manifestations of post-vaccination vasculitis. Lower level of viral antigen load in vaccination compared to COVID-19 might have contributed to favorable and self-limiting prognosis of vasculitis, indicating that the triggering factor of the skin lesion resolved in a short period of time. Vasculitis may not be considered as a contraindication of vaccination, as it appears to occur in very exceptional cases and shows favorable prognosis. Nonetheless, clinicians should monitor cutaneous adverse reactions by vaccines. Further investigations would be necessary to clarify the characteristics of vasculitis following COVID-19 vaccination. None. None declared.

Topics & Concepts